The Economic Evaluation of HPV Vaccination as a Prevention of Non-Cervical Cancer Using Modelling Approaches: A Systematic Review

Abstract

The cost-effectiveness of human papillomavirus (HPV) vaccine for non-cervical cancer including anogenital cancers and head and neck cancers has been evaluated in many countries. This is important for the decision-makers in health policy as they have a limited budget for an enormous option of health technology. The objective of this study is to systematically review the health economic studies in order to evaluate the cost-effectiveness of HPV vaccination for preventing non-cervical cancer including anogenital cancer and head and neck cancer. Approximately 496 articles were obtained from three databases (ProQuest: 430, Scopus: 40 and Pubmed: 29). The screening and selection of the literature was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The final articles were assessed by using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) checklist. Based on the review of fifteen articles, most articles concluded that HPV vaccination was cost-effective compared with current standard care. One study showed that HPV vaccination may be cost-effective if only the price is lowered. HPV vaccination is considerably a cost-effective solution to prevent non-cervical cancer based on the studies conducted in many countries particularly the ones with high income.